Ashley Kate Ragan, PharmD defines actionable proton pump inhibitor (PPI) drug-gene associations, discusses current pharmacogenomic PPI guidelines, including the 2018 Dutch Pharmacogenomic Working Group (DPWG) and 2020 Clinical Pharmacogenetic Implementation Consortium (CPIC) and reviews primary literature depicting CYP2C19 guided PPI dosing.

For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs @MayoPharmRes or the host, Garrett E. Schramm, Pharm.D., @garrett_schramm on Twitter!

You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.